Hanover Bank Launches Radio & Digital Audio Campaign to Strengthen Community Ties and Growth Strategy
ByAinvest
Thursday, Aug 7, 2025 8:02 am ET1min read
AAPG--
Ascentage Pharma is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. Its first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor, while its second approved product, Lisaftoclax, is a Bcl-2 inhibitor for treating hematologic malignancies. The company is conducting several registrational Phase III trials for these products, including POLARIS-2 for CML and GLORA for CLL/SLL [1].
The company’s management will participate in the Evercore China Biotech Summit from August 19 to 21, 2025, in Shanghai, China. They will engage in a fireside chat moderated by the Evercore ISI Research team and one-on-one investor meetings [2].
Ascentage Pharma has a robust R&D pipeline and strategic partnerships with leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent [1]. The company’s forward-looking statements include potential risks and uncertainties, such as those discussed in its filings with the SEC [1].
Investors are encouraged to tune in to the upcoming webcasts for the latest updates on Ascentage Pharma’s performance and future prospects.
References:
[1] https://www.biospace.com/press-releases/ascentage-pharma-to-participate-in-evercore-china-biotech-summit
[2] https://www.linknovate.com/news/ascentage-pharma-to-participate-in-evercore-china-biotech-summit-21067748/
AZN--
EVR--
MRK--
PFE--
Ascentage Pharma will report its 2025 six-month interim results and provide a corporate update on August 20, 2025. The company will host a Chinese language investor webcast at 9:00 pm EDT and an English language webcast at 8:00 am EDT on August 21, 2025. Ascentage Pharma is a global biopharmaceutical company developing novel therapies for cancer. Its first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor, while its second approved product, Lisaftoclax, is a Bcl-2 inhibitor for treating hematologic malignancies. The company is conducting several registrational Phase III trials for these products.
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) will report its 2025 six-month interim results and provide a corporate update on August 20, 2025. The company will host a Chinese language investor webcast at 9:00 pm EDT and an English language webcast at 8:00 am EDT on August 21, 2025.Ascentage Pharma is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. Its first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor, while its second approved product, Lisaftoclax, is a Bcl-2 inhibitor for treating hematologic malignancies. The company is conducting several registrational Phase III trials for these products, including POLARIS-2 for CML and GLORA for CLL/SLL [1].
The company’s management will participate in the Evercore China Biotech Summit from August 19 to 21, 2025, in Shanghai, China. They will engage in a fireside chat moderated by the Evercore ISI Research team and one-on-one investor meetings [2].
Ascentage Pharma has a robust R&D pipeline and strategic partnerships with leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent [1]. The company’s forward-looking statements include potential risks and uncertainties, such as those discussed in its filings with the SEC [1].
Investors are encouraged to tune in to the upcoming webcasts for the latest updates on Ascentage Pharma’s performance and future prospects.
References:
[1] https://www.biospace.com/press-releases/ascentage-pharma-to-participate-in-evercore-china-biotech-summit
[2] https://www.linknovate.com/news/ascentage-pharma-to-participate-in-evercore-china-biotech-summit-21067748/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet